🟢 Eli Lilly is trading 4.38% up in pre-market after retatrutide beats Ozempic in Phase 3 trial

Eli Lilly is trading at $1,344.79, up 4.38%, after Eli Lilly reported Wednesday that its investigational retatrutide outperformed Ozempic on blood-sugar reduction and weight loss in a head-to-head Phase 3 trial.

• At 80 weeks, average weight loss was 19.5%–20.9% with retatrutide versus 9.4% with Ozempic.
• Investors are awaiting Eli Lilly’s third-quarter results, scheduled for October 29; the company had not yet reported them in available pre-market coverage.